LEXEO THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.96 USD | -0.07% |
|
+1.75% | +4.02% |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 357.6 | 459.9 | - | - |
| Enterprise Value (EV) 1 | 236.1 | 235 | 339.5 | 459.9 |
| P/E ratio | -1.08 x | -5.58 x | -5.8 x | -6.52 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | 511 x | 204 x |
| EV / Revenue | - | - | 377 x | 204 x |
| EV / EBITDA | -3.46 x | -3.26 x | -4.47 x | -5.75 x |
| EV / FCF | -3.96 x | -3.02 x | -3.72 x | -3.97 x |
| FCF Yield | -25.2% | -33.2% | -26.9% | -25.2% |
| Price to Book | 3.15 x | 3.03 x | 2.47 x | 4.14 x |
| Nbr of stocks (in thousands) | 26,646 | 32,945 | - | - |
| Reference price 2 | 13.42 | 13.96 | 13.96 | 13.96 |
| Announcement Date | 3/11/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 0.9 | 2.25 |
| EBITDA 1 | - | -68.24 | -72 | -76 | -80 |
| EBIT 1 | - | -68.51 | -107 | -103.7 | -135.7 |
| Operating Margin | - | - | - | -11,518.77% | -6,030.66% |
| Earnings before Tax (EBT) 1 | - | -66.39 | -81.07 | -89.38 | -77.55 |
| Net income 1 | -59.28 | -66.39 | -78.28 | -84.6 | -78.21 |
| Net margin | - | - | - | -9,400.25% | -3,476.01% |
| EPS 2 | -36.34 | -12.40 | -2.501 | -2.408 | -2.142 |
| Free Cash Flow 1 | - | -59.61 | -77.93 | -91.38 | -116 |
| FCF margin | - | - | - | -10,152.78% | -5,153.33% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 9/29/23 | 3/11/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA 1 | -20.12 | - | -23.22 | -18 | -18 | -19 | - | - |
| EBIT 1 | -20.27 | -14.97 | -23.29 | -26 | -28 | -30 | -33 | -36 |
| Operating Margin | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -20.11 | -14.19 | -21.68 | -19.5 | -21 | -22 | - | - |
| Net income 1 | -20.11 | -14.19 | -21.68 | -19.06 | -20.06 | -19.56 | - | - |
| Net margin | - | - | - | - | - | - | - | - |
| EPS 2 | -1.220 | - | -0.7700 | -0.6133 | -0.6133 | -0.5700 | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 12/11/23 | 3/11/24 | 5/9/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | 121 | 225 | 120 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -59.6 | -77.9 | -91.4 | -116 |
| ROE (net income / shareholders' equity) | - | -58.5% | -55.7% | -42.1% | -43.8% |
| ROA (Net income/ Total Assets) | - | -56.1% | -46.2% | -36.7% | -38.2% |
| Assets 1 | - | 118.4 | 169.4 | 230.4 | 204.8 |
| Book Value Per Share 2 | - | 4.260 | 4.610 | 5.650 | 3.370 |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | 0.12 | 2.08 | 2.3 | 2.43 |
| Capex / Sales | - | - | - | 255.56% | 108.15% |
| Announcement Date | 9/29/23 | 3/11/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
13.96
USD
Average target price
21.4
USD
Spread / Average Target
+53.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.02% | 460M | |
| +29.77% | 49.46B | |
| +1.00% | 42.58B | |
| +49.39% | 42.49B | |
| -5.26% | 29.09B | |
| +13.68% | 26.61B | |
| -22.99% | 18.64B | |
| +8.22% | 13.16B | |
| +32.41% | 12.55B | |
| +24.01% | 12.1B |
- Stock Market
- Equities
- LXEO Stock
- Financials Lexeo Therapeutics, Inc.